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Abstract: The burden of somatic mutations and neoantigens has been associated with improved
survival in cancer treated with immunotherapies, especially non-small cell lung cancer (NSCLC).
However, there is uncertainty about their effect on outcome in early-stage untreated cases. We posited
that the burden of mutations in a specific set of genes may also contribute to the prognosis of early
NSCLC patients. From a small cohort of 36 NSCLC cases, we were able to identify somatic mutations
and copy number alterations in 865 genes that contributed to patient overall survival. Simply,
the number of altered genes (NAG) among these 865 genes was associated with longer disease-free
survival (hazard ratio (HR) = 0.153, p = 1.48 × 10−4). The gene expression signature distinguishing
patients with high/low NAG was also prognostic in three independent datasets. Patients with a high
NAG could be further stratified based on the presence of immunogenic mutations, revealing a further
subgroup of stage I NSCLC with even better prognosis (85% with >5 years survival), and associated
with cytotoxic T-cell expression. Importantly, 95% of the highly-altered genes lacked direct relation to
cancer, but were implicated in pathways regulating cell proliferation, motility and immune response.
Keywords: cancer genomics; prognosis; mutation burden; copy number; patient stratification; cancer
immunology; oncogenic pathways; patient-derived xenograft
1. Introduction
There have been extensive studies evaluating prognostic markers for early stage non-small
cell lung cancer (NSCLC) patients. These studies included genes/proteins that are overexpressed
in tumor compared to non-tumor lung tissue, mutations in specific “driver” oncogenes and tumor
suppressor genes, and gene expression profiles [1–3]. To date, no single gene/protein has been shown
consistently to be prognostic especially in large multi-institutional patient cohorts [4–7]. While
many prognostic mRNA signatures have been identified by various investigators, few of these
signatures have provided meaningful insight into the biological mechanisms that drive their prognostic
significance [8,9]. More recently, whole genome and targeted sequencing studies have observed a
relationship between the mutational load of tumors and prognosis in NSCLC [10–14]. However, these
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studies have yet to show consistent association between mutation burden and survival across multiple
cohorts. Since some non-synonymous mutations generated neoantigens that induced an anti-tumor
immune response [15–18], they have been reported to predict improved progression-free survival in
NSCLC patients treated with immunotherapies [19–21]. However, these effects of mutation burden
and neoantigens are not well characterized in early-stage NSCLC cases where immunotherapies are
currently not given.
We reported previously the genomic, transcriptomic and proteomic profiles of 36 NSCLC patients
from their primary tumors and established xenografts [22–25]. Given NSCLC tumors are genomically
heterogeneous [26], we postulated that mutations found in both primary and xenograft tumors are
more likely to correlate with patient outcomes. We applied an integrative genomics approach to identify
prognostic somatic alterations in the 36 NSCLC patients and validated their predictive performance
in multiple, much larger and independent patient cohorts (Figure 1). These results provide new
insights into genes previously not implicated in carcinogenesis itself, but that have an impact on
patient outcome.

ǂ
Figure 1. Translation of genomic information from patient-derived xenografts (PDXs) to predict patient
outcome. (A) Somatic copy number aberrations (CNA), single nucleotide variants (SNV) and gene
expression (RNA) were profiled in PDXs. The number of alterations within 865 genes (NAG) and the
associated 23 genes’ expression signature were selected using the survival of patients corresponding to
the PDXs. (B) The expression signature was used to calculate a risk score and predict overall survival
(OS) in three independent cohorts of NSCLC patients with data accessioned in the Gene Expression
Omnibus web-based data repository (GSE50081, GSE42127 and GSE68465). Survival prediction was
also tested for 518 NSCLC stage I patients from The Cancer Genome Atlas (TCGA), by using both the
expression signature and NAG. The mutations found in the 865 gene panel of the TCGA samples were
also assessed for antigenicity.
2. Results
2.1. Somatic Alteration Burden in PDX Is Correlated with Patient Survival
Atotal of 164–765geneswere characterizedwith recurrent somatic SNVsor copynumber aberration
(CNA) in 36NSCLCpatients (Figure 2A). To investigate the importance of these alterations,we correlated
their burden to the corresponding patient survival. The comparison of disease-free survival (DFS) and
overall survival (OS) of patients with these tumors with ≤343 alterations (first quartile) to patients
corresponding to patient-derived xenografts (PDXs) with >343 alterations revealed that the group
with the higher number of alterations had significantly better OS (HR = 0.366, 95% CI = 0.140–0.952,
p = 0.040) and DFS (hazard ratio (HR) = 0.294, 95% CI = 0.103–0.840, p = 0.022). The comparison of
CNAs alone with DFS showed a weaker and statistically non-significant association (HR = 0.546, 95%
CI = 0.185–1.61, p = 0.272); this also applies to OS (HR = 0.532, 95% CI = 0.197–1.43, p = 0.202). Similarly,
the number of somatic mutations alone was not significantly associated with DFS (HR = 0.568, 95% CI
= 0.179–1.79, p = 0.335) or OS (HR = 1.41, 95% CI = 0.407–4.76, p = 0.592).
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Figure 2. Association between somatic alterations found in PDXs and OS of patients. (A) A heatmap
of SNVs and CNAs across PDX models in genes that have been altered at least once. The bar graph
describes the total number of altered genes in each PDX (labeled by their ID preceded by “X”). Different
combinations of SNV point mutations and CNAs are described by the side bar graph. Circles on the bar
graph show the disease-free years to last follow-up, and the red “X” denotes the recurrence of disease
for each PDX’s matched patient, while the dashed line shows the best fit running through them. Genes
were ordered by hierarchical clustering across the samples. Kaplan–Meier curves show significant
differences, as evidenced by the hazard ratio (HR), its confidence interval and log-rank test p-value,
in the overall survival (OS) between high and low NAG in (B) all TCGA NSCLC patients and (C) only
in stage I patients.
Across the 36 tumors, a total of 3236 unique genes with somatic alterations detected in more
than a single patient were used to perform a penalized regression that was most associated with OS.
The regression model highlighted 865 genes with a non-zero contribution to the overall risk of death
(Supplementary Table S1). Remarkably, only 47 of these genes (5.4%) were identified in the Cancer
Gene Census [27]. The 36 patients were then divided into two groups based on the number of altered
genes (NAG) among the 865 genes. Patients with a high NAG had better survival (HR = 0.153, 95% CI
= 0.051–0.459, p = 1.48 × 10−4) than patients who had a lowNAG (Supplementary Figure S1A) and their
associated clinical-pathological features (summarized in Supplementary Table S2 and individually
listed in Supplementary Table S3).
2.2. Validation Using the Gene Expression Signature Associated with Somatic Alteration Burden
We hypothesized that the prognostic differences of NAGmay be recapitulated in the differentially-
expressed gene signature between the high and low NAG groups, and this may be used as a proxy of
NAG for further validation in publicly-available independent patient cohorts accessioned in the Gene
Expression Omnibus web-based data repository (GSE42127, GSE50081and GSE68465 described in
Supplementary Table S2). We identified 79 genes with differentially-expressed mRNA (>2 absolute fold
change, p< 0.05) between the two groups in our cohort of 36 patients based on theNAG (Supplementary
Table S4). Using mRNA expression profiles of the 79 genes from 127 NSCLC patients in GSE42127,
the expression scores associated with survival were calculated. Of the 79 genes, only 23 genes had
non-zero coefficients when we used penalized regression for fitting to OS in this cohort. The resulting
NAG expression signature was significantly prognostic for three independent early-stage cohorts with
mRNA expression data (GSE42127 HR 0.23, 95% CI = 0.125–0.422, p = 2.3 × 10−7; GSE50081 HR =
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0.562, 95% CI = 0.332–0.952, p = 0.029; GSE68465 HR = 0.518, 95% CI = 0.338–0.794, p = 2.2 × 10−3
(Supplementary Figure S1B–D)).
2.3. Validation in TCGA Datasets
To test the alteration burden together with the expression signature as a prognostic classifier
for NSCLC, we attempted to predict the overall survival of 221 lung adenocarcinoma (LUAD) and
173 lung squamous cell carcinoma (LUSC) cases from TCGA. We counted the NAG among the 865
genes and calculated the mRNA expression risk score for each TCGA patient tumor, then classified the
patients using the same cut-offs that were used to classify our cohort of 36 patients. All patients with a
high NAG (at least 87 altered genes) or a low expression risk score had a relatively better prognosis
(Figure 2B; HR = 0.575, 95% CI = 0.382–0.870, p = 0.0075); this also held true for stage I patients
(Figure 2C; HR = 0.391, 95% CI = 0.222–0.685, p = 6.9 × 10−4). Multivariate survival analyses of stage I
patients adjusted for age, sex, smoking history and histology confirmed that the number of alterations
was an independent predictor of good OS (HR = 0.407, 95% CI = 0.211–0.787, p = 7.7 × 10−3, Table 1).
Table 1. Multivariate survival model of NAG score with clinical-pathological factors of TCGA NSCLC
stage I patients.
Variation HR 95% CI Wald Test p-Value
Age (>65 vs. ≤65) 1.04 0.62–1.73 0.89
Sex (F vs. M) 0.85 0.51–1.43 0.54
Tobacco (smoker vs. never) 1.75 0.74–4.12 0.2
Histology (adeno vs. squamous) 0.96 0.52–1.79 0.91
Overall NAG score (low vs. high burden) 2.46 1.27–4.75 0.0077 *
NAG, number of altered genes; HR, hazard ratio; CI, confidence interval; * designates significance at p ≤ 0.05.
2.4. Immunogenic Mutations Correlate with the Best Survival and Cytotoxic T-Cell Signature
Given that alteration burden is associated with good survival outcome, we further hypothesized
that some of the mutations in the 865 genes may induce an immune response towards the tumor
through the expression of immunogenic peptides or neoantigens. We examined whether the somatic
variants within the 865 genes found in TCGANSCLC patients could encode for tumor-specific antigens
presented by MHC Class I molecules. A subset of 86 patients had at least one expressed mutated
peptide with highMHC I binding affinity against both HLA-A alleles, and this immunogenic group had
significantly better OS (Supplementary Figure S2A; HR = 0.536, CI = 0.341–0.8419, p = 0.0068). Among
NSCLC stage I patients, 47 were classified as having immunogenic mutations and had significantly
better OS (Figure 3A; HR = 0.266, CI = 0.1068–0.6619, p = 0.0044), even after adjusting for other clinical
factors (Table 2). In comparison, patients stratified using all possible neoantigens, beyond those in the
panel of 865 genes, had no significant difference (p < 0.01) in overall survival (Supplementary Table S5).
By combining this immunogenicity classifier with the alteration burden based on NAG, we were able
to identify patients with extremely good prognosis. Stage I patients with both immunogenic and
high NAG tumors had significantly better survival than patients with either low or high NAG alone
(Figure 3B; HR = 0.0807, CI = 0.02315–0.2813, p = 7.8 × 10−5).
The RNA expression profiles from these two groups of patients were analysed further for immune
components. Immune cell population estimates from TIMER [28] revealed moderately, but not
significantly higher proportions of B-cells, dendritic cells, and CD8 T-cells in high NAG patient tumors
with immunogenic peptides compared to those without neoantigens (Figure 3C). Focusing specifically
on markers of cytotoxic T-cells in Figure 3D, we also found in high NAG tumors with immunogenic
peptides significantly higher (p < 0.05) expression of CD8A, granzyme B (GZMB) and perforin (PRF1).
Previously, cytokines CCL5, CXCL9, CXCL10 and IL16 were found to be associated with cytotoxic
T-cells [29]. We found CCL5, CXCL9 and CXCL10 to be significantly more highly expressed in our
group with immunogenic peptides. In contrast, there were no consistent differences in immune cell
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populations or cytotoxic T-cell markers between high and low NAG patients without immunogenic
peptides (Supplementary Figure S2B,C).
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Figure 3. TCGA NSCLC patients stratified by immunogenic neoantigens. (A) Stage I patients (47 with
neoantigens, 171 without neoantigens) are grouped into those with immunogenic neoantigens and
those with none. Hazard ratios and log-rank p-values compare immunogenic patient tumors to
non-immunogenic patient tumors. (B) The overall survival differences of stage I patients were classified
based on the presence of immunogenic neoantigens and the number of altered genes. Immunogenic
and high-NAG patient tumors (green, 37 patients) vs. non-immunogenic and low-NAG patient tumors
(red, 23 patients) show HR = 0.0807, p = 7.8 × 10−5. Immunogenic and high-NAG tumors (green)
vs. non-immunogenic and high-NAG patient tumors (blue, 147 patients) show HR = 0.229, p = 0.013.
Non-immunogenic and high-NAG tumors (blue) vs. non-immunogenic and low-NAG patient tumors
(red) show HR = 0.309, p = 7.9 × 10−5. High NAG patients with and without neoantigens were
contrasted based on the relative abundance of immune cell types estimated by the TIMER algorithm
(C), and the RNA expression of cytotoxic T-cell markers (D). Significant differences for each component
are marked (t-test p-value * <0.05; ** <0.01).
Table 2. Multivariate survival model of the immunogenicity factor with clinical-pathological factors of
TCGA NSCLC stage I patients.
Variation HR 95% CI Wald Test p-Value
Age of diagnosis (≤65 y vs. >65 y) 0.929 0.545–1.583 0.7865
Gender (male vs. female) 0.871 0.524–1.447 0.5929
Smoking history (last 15 y; yes vs. no) 0.751 0.434–1.302 0.3085
Histology (adeno vs. squamous cell) 0.677 0.392–1.169 0.1615
Immunogenicity (≥1 neoantigen vs. 0 neoantigens) 0.296 0.119–0.740 0.00919 *
* designates significance at p ≤ 0.05.
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2.5. Prognostic Alterations Enriched in Genes Involved in Extracellular Signaling
To investigate the alternate or additional mechanisms by which alteration burden might be
impeding cancer progression, pathway enrichment analyses were performed on the 865 genes.
The most enriched pathways involved BARD1 signaling, Janus kinase activity, integrin signaling and
extracellular matrix interactions (Figure 4A; hyper-geometric test p < 0.01). Within these pathways,
a number of genes were altered more frequently across TCGA cases in the group of low-risk patients
with better survival (Figure 4B). Inactivating alterations, which deactivate Wnt signaling, were most
frequent in CTNNB1 (23.1%) andWNT5A (22.8%), along with copy gains in the tumor suppressors
NHERF1 (16.4%) and NF2 (13.1%). The high frequency of copy gains occurring in ITGA10 (20.9%),
COL20A1 (17.9%) and COL8A1 (26.5%) suggested that cell adhesion to the extracellular matrix may
be affected. These highly-altered genes and pathways have been known to control specific cellular
functions such as proliferation, motility and adhesion.
In order to evaluate the effect of these pathway alterations on cell functionality, we selected three
NSCLC cell lines (H1573, A549, HCC827) with different levels of NAG and expression risk scores
(Figure 5A). The three cell lines had different patterns of expression for the NAG genes we found
frequently altered in TCGA cases (Figure 5B). Cell line H1573 had 45 NAG, while A549 and HCC827
had 13 and 18, respectively. HCC827 had the fastest rate of proliferation over 80 h of growth and the
highest number of invading cells across a Matrigel membrane after 48 h (Figure 5C,D). In contrast,
H1573, which had the highest NAG, had a much slower rate of proliferation and invasion (p = 0.0145).
Furthermore, HCC827 moved the fastest in a 24-h motility assay compared to the other two cell lines
(Figure 5E).
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LOF alteration = % of TCGA NSCLC patients with somatic mutation OR copy loss  
GOF alteration = % of TCGA NSCLC patients with copy gain OR amplification 
Pathway terms enriched at adjusted P-value < 0.01  
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Figure 4. Enriched pathways and biological processes for genes in NAG. (A) Pathways in Pathway
Commons and Gene Ontology were enriched for NAG genes. Bar plots show the proportions of
NAG genes within each pathway that were classified as gain of function (GOF) or loss of function
(LOF) alterations in TCGA cases. (B) A diagram of enriched pathways identified from NAG and their
associated expression signature genes. The main pathways that emerged included Wnt signaling,
integrin signaling and actin cytoskeleton regulation. Blue nodes identify copy number loss or
inactivating mutation indicating loss of function (LOF), and red nodes indicate copy number gain
indicating gain of function (GOF). Percentages in brackets represent the difference in alteration frequency
between patients of low and high mortality risk, respectively, as classified by the NAG and the NAG
expression score for TCGA NSCLC tumors. The color intensity reflects the proportion of tumors with
the gene alteration. ECM = extracellular matrix.
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Figure 5. Functional impact of altered and differentially-expressed genes on cancer cells. (A) The
number of genes (out of 865 genes) with somatic SNV or CNAwas tallied for routinely-used lung cancer
cell lines. Three lung cancer cell lines with differing overall NAG (based on quartiles) and different risk
scores for NAG associated expression signature were compared to each other in functional assays. (B) A
heatmap of RNA expression level scaled across cell lines for NAG genes commonly altered in TCGA is
shown for the three lung cancer cell lines. (C) Proliferation of the three cultured cell lines was estimated
by electrical impedance (cell index) over time. (D) Invasion of cells across trans-well membranes coated
with Matrigel was counted. (E) Cell motility was measured by a time-lapse wound-healing assay. The
rates of wound area travelled by cells were 15.42 µm/hr for HCC827, 2.64 µm/h for A549 and 1.98 µm/h
for H1573.
3. Discussion
We have shown that the number of somatic alterations among 865 genes is associated with
better prognosis in early stage NSCLC patients. These prognostic alterations included not only
non-synonymous mutations, but also copy number alterations, and they have a corresponding gene
expression signature derived fromdifferentially-expressed genes between high and lowNAGsvalidated
in three cohorts of early stageNSCLC. For stage I TCGApatients, we further showed that the integrative
NAG score was able to classify patients into three distinct subpopulations with low NAG, high NAG
and high NAG with neoantigens. These subpopulations were distributed equally in their frequency
of clinical features (Supplementary Table S6). Pathway analysis of the panel of 865 genes revealed
that the majority of the mutations had not been implicated in driving cancer pathogenesis, but were
associated with processes relating to immune activation, tumor cell–extracellular matrix interactions
and cell motility, which were supported by cell line experiments. These findings provide evidence
that high-level somatic genomic aberrations involving non-cancer-associated genes may confer better
prognosis through the generation of neoantigens, impairment of cellular functions involved in tumor
cells and stroma interaction and motility.
Few recent investigations of mutation or neoantigen burden in early stage or untreated lung
cancers provided contradictory evidence for the directionality of the relationship between burden and
survival [10–12]. These studies relied on measuring burden by counting all point mutations across
genomes and, thus, were sensitive to mutation calling error (Supplementary Table S7). In contrast,
our burden measure of counting the number of genes with at least one alteration (point mutation,
CNA, neoantigen or RNA expression) may be more robust to variant calling errors and variation in the
number of variants within each gene.
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Smaller targeted gene panels recently have been shown to be clinically effective at measuring
overall tumor mutation burden in mostly known cancer driver genes [10,15]. Our observations indicate
that mutation burden in non-driver genes may also have an effect on patient outcome. The mechanism
by which alteration burden in gene sets affects cancer progression and patient survival remains unclear,
but it has been hypothesized that excessive genomic instability can lead to deleterious mutations and
gene losses that impede tumor growth [30,31]. Greater DNA damage, especially due to dysregulation
of DNA repair mechanisms, could result in deleterious mutations or copy number losses in many of
the 865 genes that are associated with cell adhesion, motility and integrin signaling, cellular functions
that are likely also essential in the phenotypic manifestation of malignant tumor cells [32,33]. Integrin
signaling is a major pathway contributing to cancer cell survival and has been a target for antagonists
to inhibit tumor growth [34]. Therefore, the occurrence of copy loss alterations in integrin pathway
genes may mitigate tumor cell malignancy and is thus a marker for less aggressive tumors in patients
with good survival outcomes.
Somatic mutation burden has been correlated with neoantigen load and T-cell infiltration in
NSCLC and melanoma [14,35–37], yet there is a lack of evidence for this relationship in early-stage
cancers, which are predominantly untreated with therapeutics. Our assessment of neoantigen load
among the 865 genes is the first to show that even in stage I NSCLC cancer without immunotherapy,
the presence of neoantigens and high mutation burden is correlated with T-cell expression. Previously,
mutation burden and neoantigen load were used to identify patients with good prognosis following
immunotherapy treatment, such as immune checkpoint inhibitors, but there has been debate about
whether both markers are needed given that they select for a similar subgroup of patients [14,15,38].
Even though all the patients we identified with immunogenic mutations (neoantigens) were also
classified as high alteration burden and as having long OS (>85% surviving longer than five years),
we identified a unique subgroup of patients with low alteration burden and no immunogenic mutations
that had far worse OS (median survival of two years). In contrast to previous reports about the
clonality of neoantigens that are prognostic [14,16], the immunogenic mutations we used for patient
stratification did not show evidence of being subclonal compared to other mutations based on their
variant allele fractions (Supplementary Figure S3). Our criteria for immunogenicity prediction may
have been overly stringent, resulting in far fewer neoantigens found in each patient compared to other
studies and may have led to our approach missing some clonal or subclonal neoantigens.
4. Materials and Methods
4.1. Patient and NSCLC PDX for Genomics Profiling
This study involved 36 patients [22–24,39] whose NSCLC tumors were surgically resected and
successfully engrafted as PDX models in non-obese diabetic (NOD) severe immune deficient (SCID)
mice. Short indels and single nucleotide variants (SNV) were identified from whole exome sequencing
in the primary and PDX tumors. Copy number alterations were profiled using the HumanOmni 2.5
BeadChip SNP array and processed in accordance with previous reports [22–24,39]. The average log
likelihood ratio (LRR) for each gene was used to determine copy gains (LRR > 0.5) and copy loss
(LRR < −0.5).
4.2. TCGA Patients
Publishedmutation, copy number, RNA-seq and clinical datawere downloaded for LUAD [40] and
LUSC [41] patients on cBioPortal, using the cgdsr R package [42], and clinical data were downloaded
using the FireBrowseR R package [43]. Copy number gains and losses were determined using an LRR
cut-off of ±0.5. RNA expression data in the RNA-seq by expectation maximization (RSEM) scale from
RNA-seq were transformed by the asinh function for survival analysis.
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4.3. Stratification by High-Level Mutation Burden
To identify genomic alterations associated with patient survival from somatic profiles, we first
defined a gene as “altered” if there was a somatic non-synonymous mutation, copy number gain or
copy number loss. Genes altered only in one patient tumor were removed. The resulting alteration
profiles across patients were fitted to the overall survival (OS, up to five years) of the corresponding
patients. ElasticNet from the R package “glmnet” Version 1.9-8 was used for the regression fit with
alpha at 0.1 and the best fitting model selected from the maximum of the deviance ratio. In the
ElasticNet model, 865 genes had non-zero coefficients.
The number of somatic alterations among 865 genes (NAG) was used as the risk score for each
TCGA patient. The risk scores were dichotomized at the first quartile to assign patients to one of the
prognostic arms (high vs. low number of alterations). The proportions of DFS and OS were calculated
using the Kaplan–Meier method, and the difference between curves was tested using the log-rank test.
The OS is the time between the date of diagnosis to the date of death or last follow-up, and the DFS
is the date of diagnosis to the date of death, or relapse or last follow-up. All reported hazard ratios
(HR) scores and p-values used the Kaplan–Meier method unless reported as multivariate analyses.
A Cox proportional hazards model was used to fit survival times to the number of altered genes while
adjusting for other clinical factors including age, stage and smoking status. The significance for the
Cox proportional hazards model was based on the Wald test. The R code for conducting this validation
test on TCGA datasets can be found at https://github.com/TransAnalytics/cancer_prog_prediction.
4.4. Stratification by Gene Expression Profiles Corresponding to NAGs
The mRNA expression profiles in the 36 NSCLC tumors were measured as previously described
and accessioned in the Gene Expression Omnibus (GEO) data repository (GSE68929) [22–24,39].
79 differentially-expressed genes (absolute fold change >2 and t-test p-value <0.05) between the high
and low number of genomic alterations were identified. The expression profiles of these genes from
the UT Lung Spore dataset (GSE42127) [8] were fitted to the OS using ElasticNet. ElasticNet’s lambda
parameter was selected from 5-fold cross-validated likelihood, and the alpha parameter was set at
0.1. The coefficients from the ElasticNet model, which formed the 23-gene prognostic classifier, were
summed to create an expression risk score for each patient. An expression risk score ≥0.17 was
associated with low NAGs, whereas an expression risk score <0.17 was associated with high NAGs.
The cut-off at 0.17 was at the third quartile of risk scores, which was consistent with the first quartile
cut-off for NAG. All reported survival differences were tested using the Wald test within the Cox
proportional hazards model, and follow-up of patients was measured up to 5 years. Validation of
NAG expression risk scores was performed on the Director’s Challenge Consortium for Molecular
Classification of Lung Adenocarcinoma dataset with a total of 442 samples (GSE68465) [1] and the
UHN181 cohort of 181 NSCLC patients (GSE50081) [44].
4.5. Estimating Immunogenicity
Non-synonymous mutations causing amino acid changes were identified among the 865-gene
panel for TCGA patients. Protein sequences were acquired from the UniProt reviewed canonical
human proteome UP000005640 FASTA file. Windows of 8–11 amino acids in length were derived by
applying non-synonymous SNVs to their respective protein sequence and using all 8–11mer amino
acid peptides containing the altered amino acid. The 8–11mer altered peptides for each patient were
input into NetMHCpan v3.0 [45] along with both of the patient’s supertyped HLA-A alleles to calculate
their predicted HLA-A binding affinity values for each altered peptide. The 4-digit HLA types for the
patients were sourced from The Cancer Immunome Atlas [46], which used Optitype [47] to call the
HLA-A alleles from RNA-seq FASTQ files. The HLA types were supertyped into standard categories
prior to carrying out the HLA-A binding affinity prediction analysis [48].
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We defined peptides as antigenic if they had an HLA-A binding affinity below 500 nM with both
HLA-A alleles. In addition, antigenic peptides’ genes had to be expressed above the median expression
level for that gene calculated across all patients in order for the peptides to be considered immunogenic,
and the patient HLA-A gene needed to be expressed above the median HLA-A expression level across
all patients. Patients were considered to have immunogenic peptides that could potentially trigger an
immune response by fulfilling these three conditions: strong binding affinity, high expression of the
antigenic peptide to ensure they are clonal and high expression of the MHC-I receptor. Patients were
stratified based on whether or not they had above the median number of immunogenic peptides (1 or
more) as outlined above, either alone, or in combination with the NAG score. A Cox proportional
hazards model was used to calculate the effect size/risk factor associated with the presence/absence of
these features, along with the p-values for the differences between patient groups.
4.6. Pathway Enrichment
Gene set enrichment was performed on the 865 genes using the database for annotation,
visualization and integrated discovery (DAVID) and WebGestalt [49]. Using the DAVID API,
120 “adhesion”-, “integrin”- and “extracellular matrix”-related genes were isolated from the initial
gene set. Of these, the list was refined further by filtering for those with alteration frequencies greater
than 10% among TCGA patients. Pathway memberships of genes were extracted from GeneCards,
KEGG and Pathway Commons [50] and visualized by Cytoscape (v3.2.0). Nodes on the edges of the
network that did not connect to any of the main cancer pathways were removed (i.e., CLTC and EPN1).
The genes were arranged by cellular location into either the extracellular matrix (ECM) and plasma
membrane or the cytoplasm.
4.7. In Vitro Functional Assays
Cell proliferation assays were performed on A549, H1573 and HCC827 cells as described
previously [51]. In brief, 5000 cells were seeded per well of an E-plate. Impedance was measured
every 15 min for 80 h. Growth curves were constructed using the xCELLigence platform (ACEA
Biosciences, San Diego, CA, USA). Tumor cell invasion was assessed in vitro by the reconstituted
basement membrane (Matrigel) invasion assay [52], which was performed using 8-µm polycarbonate
filters coated with reconstituted basement membrane (Matrigel; BD Bio-sciences, San Jose, CA, USA).
The motility of cells was measured after seeding in a plastic-bottomed 24-well dish and incubated for
12 h. FBS was added to the medium, and the migration assay was carried out for 24 h. Images were
acquired every 20 min for approximately 24 h using a 10× phase objective.
5. Conclusions
Extensive efforts by many laboratories have attempted to identify cancer genomic features that
correlate with the prognosis of NSCLC patients [3,53]. Very few studies have attempted to conduct
biological validation of the prognostic genes identified in these prognostic signatures [9,54]. In contrast,
Tang et al. used a systems biology approach integrating genome-wide functional (RNAi) data and
genetic aberration data to derive a 12-gene prognostic signature that is also predictive for adjuvant
chemotherapy benefits in NSCLC. Our study represents a translational research approach to identify
genomic features of NSCLC tumor cells that could confer the prognostic implication in patient clinical
outcome. We have provided evidence that the good prognostic impact of a high level of genomic
aberrations was contributed by genes that are not considered oncogenic drivers in NSCLC through
potential neoantigen generation and impairment of proteins that remain essential for tumor cells to
manifest their malignant phenotypes.
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